Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACCL1633||COG||The Effectiveness of Lactobacillus plantarum (LBP, IND #17339) In preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)||Pediatric CIRB||Available to Open|
|10193||ETCTN||Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma and Primary Mediastinal Large B-cell Lymphoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|S1914||SWOG||A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|10330||ETCTN||A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|NRG-BR003||NRG||A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1305||ECOG||A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1616||SWOG||A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-CC007CD||NRG||Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy||Cancer Prevention and Control CIRB||Available to Open|
|10067||ETCTN||A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy||Adult CIRB - Early Phase Emphasis||Available to Open|
|10104||ETCTN||A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer.||Adult CIRB - Early Phase Emphasis||Available to Open|